Recent reports suggest XIAP may have a similar role in pancreatic cancer, as XIAP inhibition similarly restored TRAIL sensitivity by converting cytotoxic signaling from a Type II to a Type I death receptor pathway in several TRAIL-resistant cancer cell lines [33], [34], [35]. This evidence concerns the gene TNFSF10 and familial pancreatic carcinoma.